160 related articles for article (PubMed ID: 35302688)
1. Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctivitis in an environmental exposure chamber.
de Blay F; Gherasim A; Domis N; Choual I; Bourcier T
Clin Exp Allergy; 2022 Sep; 52(9):1091-1100. PubMed ID: 35302688
[TBL] [Abstract][Full Text] [Related]
2. Birch allergen challenges in allergic conjunctivitis using standard conjunctival allergen challenge and environmental exposure chamber.
Gherasim A; Fauquert JL; Domis N; Siomboing X; de Blay F
Clin Transl Allergy; 2021 Aug; 11(6):e12053. PubMed ID: 34429874
[TBL] [Abstract][Full Text] [Related]
3. [Interest of environmental exposure chambers in the evaluation of allergic conjunctivitis].
Ehret M; Bourcier T; Domis N; Gherasim A; Speeg-Schatz C; de Blay F
J Fr Ophtalmol; 2020 Nov; 43(9):920-928. PubMed ID: 33004194
[TBL] [Abstract][Full Text] [Related]
4. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.
Denis D; Bloch-Michel E; Verin P; Sebastiani A; Tazartes M; Helleboid L; Di Giovanni A; Lecorvec M
Br J Ophthalmol; 1998 Oct; 82(10):1135-8. PubMed ID: 9924299
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis.
Leonardi A; Papa V; Milazzo G; Secchi AG
Cornea; 2002 Jul; 21(5):476-81. PubMed ID: 12072722
[TBL] [Abstract][Full Text] [Related]
6. [Intra-annual and seasonal allergic conjunctivitis treatment: comparison of two therapeutic protocols].
Lazreg S; Colin J; Renault D; Hartani D
J Fr Ophtalmol; 2008 Dec; 31(10):961-7. PubMed ID: 19107071
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl-aspartyl glutamic acid (NAAGA) topical eyedrops in the treatment of giant papillary conjunctivitis (GPC).
Meijer F; Pogany K; Kok JH; Kijlstra A
Doc Ophthalmol; 1993; 85(1):5-11. PubMed ID: 7910133
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis.
Gündüz K; Uçakhan O; Budak K; Eryilmaz T; Ozkan M
Ophthalmic Res; 1996; 28(2):80-7. PubMed ID: 8792357
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.
Leonardi A; Bremond-Gignac D; Bortolotti M; Violato D; Pouliquen P; Delval L; Grouin JM; Fregona IA
Br J Ophthalmol; 2007 Dec; 91(12):1662-6. PubMed ID: 17585003
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial.
Fukushima A; Ebihara N
Adv Ther; 2014 Oct; 31(10):1045-58. PubMed ID: 25269854
[TBL] [Abstract][Full Text] [Related]
12. The use of environmental exposure chambers in studies related to ocular surface effects.
Gherasim A; Bielory L
Curr Opin Allergy Clin Immunol; 2023 Oct; 23(5):409-414. PubMed ID: 37459277
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-aspartyl-glutamic acid inhibits cellular recruitment and mediator release during the late allergen-induced nasal reaction.
Miadonna A; Milazzo N; Salmaso C; Cottini M; Lorini M; Tedeschi A
Eur J Clin Pharmacol; 1998 Sep; 54(7):515-20. PubMed ID: 9832292
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of topical pranoprofen and fluorometholone in cases with chronic allergic conjunctivitis.
Li Z; Mu G; Chen W; Gao L; Jhanji V; Wang L
Cornea; 2013 May; 32(5):579-82. PubMed ID: 23023407
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new anti-allergic agent: the magnesium salt of N-acetyl-aspartyl-glutamic acid on experimental allergic inflammation of the rabbit eye.
Lapalus P; Moulin G; Bayer V; Fredj-Reygrobellet D; Elena PP
Curr Eye Res; 1986 Jul; 5(7):517-22. PubMed ID: 3743112
[TBL] [Abstract][Full Text] [Related]
19. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
20. Birch-induced allergic rhinitis: Results of exposure during nasal allergen challenge, environmental chamber, and pollen season.
Gherasim A; Dietsch F; Beck M; Domis N; de Blay F
World Allergy Organ J; 2023 Jul; 16(7):100801. PubMed ID: 37520615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
